Senores Pharmaceuticals saw its shares rally more than 4%after the company announced the commercial launch of Deferiprone Tablets USP in 500 mg and 1000 mg strengths in the United States. The newly launched product is bioequivalent and therapeutically equivalent to Ferriprox Tablets, marketed by Chiesi USA, Inc., and will be distributed through Dr. Reddy’s Laboratories Inc. This move marks another step forward in Senores’ efforts to expand its footprint within the competitive U.S. generics market.
In its announcement, the company highlighted that the introduction of Deferiprone represents a meaningful milestone in its long-term strategy to enter high-value therapeutic areas with limited competition. Swapnil Shah, Managing Director of Senores Pharmaceuticals Limited, explained that the launch fits squarely within the company’s focus on identifying speciality segments where patient access to affordable treatment options remains inadequate. He noted that Deferiprone is designed to address specific unmet clinical needs while also supporting the company’s broader growth ambitions in the U.S. market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
